26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced detailed results from the PIONEER trial of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (SM)....
, Feb. 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced detailed results from the PIONEER trial of AYVAKIT® (avapritinib) in patients with indolent systemic ...
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-positive-data-from-pioneer-trial-of-ayvakit-avapritinib-in-indolent-systemic-mastocytosis-at-2023-aaaai-annual-meeting-301738110.html...
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of AYVAKIT® (avapritinib) in indolent systemic mastocytosis (SM) at the 2023 American Acad...